Actinium Pharmaceuticals, Inc. (ATNM)
NYSEAMERICAN: ATNM · Real-Time Price · USD
1.480
-0.050 (-3.27%)
Oct 30, 2026, 4:00 PM EDT - Market closed
Actinium Pharmaceuticals Employees
Actinium Pharmaceuticals had 27 employees as of June 30, 2026. The number of employees did not change compared to the same quarter last year. That makes Actinium Pharmaceuticals the 37,479th largest employer in the world and 5,256th in the United States.
Employees
27
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$1,299,630
Profits / Employee
$418,815
Market Cap
46.53M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2026 | 27 | 0 | - |
| Mar 31, 2026 | 25 | -6 | -19.35% |
| Dec 31, 2025 | 25 | -12 | -32.43% |
| Sep 30, 2025 | 25 | -12 | -32.43% |
| Jun 30, 2025 | 27 | -10 | -27.03% |
| Mar 31, 2025 | 31 | -18 | -36.73% |
| Dec 31, 2024 | 37 | -12 | -24.49% |
| Sep 30, 2024 | 37 | -12 | -24.49% |
| Dec 31, 2023 | 49 | 0 | - |
| Dec 31, 2022 | 49 | 17 | 53.13% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Caribou Biosciences | 97 |
| Xilio Therapeutics | 76 |
| Mereo BioPharma Group | 39 |
| Elicio Therapeutics | 33 |
| INmune Bio | 21 |
| LeonaBio | 19 |
| ImageneBio | 18 |
| Instil Bio | 17 |
ATNM News
- 2 days ago - Actinium Pharmaceuticals Announces Inducement Grant to New Employee - PRNewsWire
- 9 days ago - Actinium Pharmaceuticals to Highlight First-in-Human Phase 1 Study of ATNM-400 a HER3-Targeted Non-PSMA Radiotherapy in Prostate Cancer at ESMO 2026 - PRNewsWire
- 12 days ago - Actinium Pharmaceuticals’ ATNM-400 shows anti-tumor activity in prostate cancer - TheFly
- 12 days ago - Actinium Pharmaceuticals Unveils ATNM‑400 Data at EANM 2026 with a First‑In‑Human HER3‑Targeted Radiotherapy Approach Beyond PSMA in Prostate Cancer - PRNewsWire
- 12 days ago - Actinium Pharmaceuticals Presents EANM 2026 Results Reinforcing ATNM-400's Pan-Tumor Potential Across Lung, Colorectal and Ovarian Cancer Models - PRNewsWire
- 13 days ago - Actinium Pharmaceuticals to Showcase ATNM-400's First-in-Human Clinical Data in Prostate Cancer and Preclinical Results in Lung Cancer Supporting Pan-Tumor Potential Today at EANM 2026 - PRNewsWire
- 16 days ago - Actinium Pharmaceuticals Announces Inducement Grants to New Employees - PRNewsWire
- 16 days ago - Actinium Pharmaceuticals to present ATNM-400 data at EANM - TheFly